Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence.

Lin HK, Chen Z, Wang G, Nardella C, Lee SW, Chan CH, Yang WL, Wang J, Egia A, Nakayama KI, Cordon-Cardo C, Teruya-Feldstein J, Pandolfi PP.

Nature. 2010 Mar 18;464(7287):374-9. doi: 10.1038/nature08815. Erratum in: Nature. 2010 Jul 15;466(7304):398. Chan, Chan-Hsin [corrected to Chan, Chia-Hsin].

2.

Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression, and metastasis.

Wang G, Chan CH, Gao Y, Lin HK.

Chin J Cancer. 2012 Apr;31(4):169-77. doi: 10.5732/cjc.011.10319. Epub 2011 Dec 23. Review.

3.

The role of Skp2 and its substrate CDKN1B (p27) in colorectal cancer.

Bochis OV, Irimie A, Pichler M, Berindan-Neagoe I.

J Gastrointestin Liver Dis. 2015 Jun;24(2):225-34. doi: 10.15403/jgld.2014.1121.242.skp2. Review.

4.

Activation of p53 by oncogenes.

Lowe SW.

Endocr Relat Cancer. 1999 Mar;6(1):45-8. Review.

5.

Tumor suppressors and oncogenes in cellular senescence.

Bringold F, Serrano M.

Exp Gerontol. 2000 May;35(3):317-29. Review.

PMID:
10832053
6.

Skp2 Inhibitors: Novel Anticancer Strategies.

Lee Y, Lim HS.

Curr Med Chem. 2016;23(22):2363-79. Review.

PMID:
27160538
7.

Control of DNA synthesis and mitosis by the Skp2-p27-Cdk1/2 axis.

Pagano M.

Mol Cell. 2004 May 21;14(4):414-6. Review.

8.

Dynamics of ARF regulation that control senescence and cancer.

Ko A, Han SY, Song J.

BMB Rep. 2016 Nov;49(11):598-606. Review.

9.

Novel ARF/p53-independent senescence pathways in cancer repression.

Chan CH, Gao Y, Moten A, Lin HK.

J Mol Med (Berl). 2011 Sep;89(9):857-67. doi: 10.1007/s00109-011-0766-y. Epub 2011 May 19. Review.

10.

E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers.

Masumoto K, Kitagawa M.

Curr Cancer Drug Targets. 2016;16(2):130-5. Review.

PMID:
26560119
11.

IL-6/STAT3/ARF: the guardians of senescence, cancer progression and metastasis in prostate cancer.

Pencik J, Wiebringhaus R, Susani M, Culig Z, Kenner L.

Swiss Med Wkly. 2015 Dec 21;145:w14215. doi: 10.4414/smw.2015.14215. eCollection 2015. Review.

12.

Skp2: a novel potential therapeutic target for prostate cancer.

Wang Z, Gao D, Fukushima H, Inuzuka H, Liu P, Wan L, Sarkar FH, Wei W.

Biochim Biophys Acta. 2012 Jan;1825(1):11-7. doi: 10.1016/j.bbcan.2011.09.002. Epub 2011 Sep 22. Review.

13.

Forging a signature of in vivo senescence.

Sharpless NE, Sherr CJ.

Nat Rev Cancer. 2015 Jul;15(7):397-408. doi: 10.1038/nrc3960. Review. Erratum in: Nat Rev Cancer. 2015 Aug;15(8):509.

PMID:
26105537
14.

[DDX5 is a novel targeting protein of tumor suppressor ARF].

Tago K, Funakoshi-Tago M.

Seikagaku. 2016 Apr;88(2):207-10. Review. Japanese. No abstract available.

PMID:
27192872
15.

miR-20a and miR-290, multi-faceted players with a role in tumourigenesis and senescence.

Rizzo M, Mariani L, Pitto L, Rainaldi G, Simili M.

J Cell Mol Med. 2010 Nov;14(11):2633-40. doi: 10.1111/j.1582-4934.2010.01173.x. Review.

16.

Pro-senescence therapy for cancer treatment.

Nardella C, Clohessy JG, Alimonti A, Pandolfi PP.

Nat Rev Cancer. 2011 Jun 24;11(7):503-11. doi: 10.1038/nrc3057. Review.

PMID:
21701512
17.

Senescence-Derived Extracellular Molecules as Modulators of Oral Cancer Development: A Mini-Review.

Parkinson EK, James EL, Prime SS.

Gerontology. 2016;62(4):417-24. doi: 10.1159/000440954. Epub 2015 Dec 3. Review.

18.

Senescence as biologic endpoint following pharmacological targeting of receptor tyrosine kinases in cancer.

Francica P, Aebersold DM, Medová M.

Biochem Pharmacol. 2017 Feb 15;126:1-12. doi: 10.1016/j.bcp.2016.08.022. Epub 2016 Aug 27. Review.

PMID:
27574725
19.

Bypassing cellular senescence by genetic screening tools.

Vergel M, Carnero A.

Clin Transl Oncol. 2010 Jun;12(6):410-7. doi: 10.1007/s12094-010-0528-2. Review.

PMID:
20534396
20.

Immunology in the clinic review series; focus on cancer: multiple roles for the immune system in oncogene addiction.

Bachireddy P, Rakhra K, Felsher DW.

Clin Exp Immunol. 2012 Feb;167(2):188-94. doi: 10.1111/j.1365-2249.2011.04514.x. Review.

Supplemental Content

Support Center